Positive effect of increasing dosage of selective antimuscarinics on the main symptoms of overactive bladder


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Overactive bladder (OAB) is a heavy urination disorder that affects at least 17% of the population older than 40 years. As a rule, for the treatment of OAB drug therapy is typically used. Currently, the most common drugs for the treatment of symptoms of OAB include preparations that block muscarinic receptors of the bladder. Solifenacin has the highest selectivity for the bladder among all m-cholinoblockers. The studies presented in this article show that the flexible dosing strategy can be effective in improving the symptoms of OAB, with minimal impact on tolerance. According to numerous studies, it is possible to confirm a positive effect of possibility of increasing the dosage of the drug solifenacin (vesicare) in the treatment of major symptoms of OAB, and actualize the need for use of solifenacin 10 mg at the starting of therapy. This drug has no significant effect on cognitive function in elderly patients, in contrast to oxybutynin. Thus, due to the optimal balance of efficacy and safety, solifenacin at a dose of 10 mg provides greater treatment adherence compared to other m-anticholinergics.

Full Text

Restricted Access

About the authors

Z. K Gadzhieva

SRI of Uronephrology and Human Reproductive Health First MSMU n.a. I.M. Sechenov

Email: zaida-gadzhieva@rambler.ru
MD, Leading Researcher

References

  1. Bulmer P., Abrams P. The overactive bladder. Rev Contemp Pharmacother. 2000; 11: 1-11.
  2. Abrams P., Wein A. Introduction: overactive bladder and treatments. BJU. 2000; 85(3): 1-2.
  3. Wang P., Luthin G.R., Ruggieri M.R. Muscarinic acetylcholine recepnors subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol. Exp. Ther. 1995; 273: 959-966.
  4. Levin R.M., Haugaard N., O'Connor L. et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol. Urodyn. 2000; 19(5): 609-29.
  5. Hashim H., Abrams P. Drug treatment of overactive bladder. Drugs. 2004; 64(15): 1643-1656.
  6. Versi E., Cardozo L., Studd J., Brincat M. Cooper D. Urinary disorders and the menopause. Menopause. 1995; 2(2): 89-95.
  7. Гаджиева З.К. Функциональное состояние нижних мочевых путей и медикаментозная коррекция нарушений мочеиспускания у женщин в климактерии. Дис.. канд. мед наук. М., 2001. 188 с.
  8. Foldspang A., Mommsen, S. Adult female urinary incontinence and childhood bedwetting. J Urol. 1994; 152: 85.
  9. Eiberg H., Shaumburg H.L., Von Gontard A. et al. Linkage study of a large Danish 4-generation family with urge incontinence and nocturnal enuresis. J Urol. 2001; 166: 2401.
  10. Abrams P., Cardozo L., Fall M. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol. Urodyn. 2002; 21: 167-78.
  11. Andersson K. Antimuscarinics for treatment of overactive bladder. Lancet. 2004; 3: 46-53.
  12. Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother. 2000; 11: 13-27.
  13. Ohtake A., Ukai M., Hatanka T. et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol. 2004; 492(2-3): 243-250.
  14. Chapple C.R., Martinez-Garcia R., Selvaggi L. et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. EU. 2005; 48: 464-470.
  15. Chapple C., Rechberger T., Al-Shukri S. et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004; 93: 303-310.
  16. Chapple C.R. Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU Int. 2009; 104(7): 960-967.
  17. Wagg A., Compion G., Fahey A. et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012; 110: 1767-1774.
  18. Govier F.E., Smith N., Uchida T. Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial. Urology. 2010: 4: 11-20.
  19. Keith A. Wesnes Expert Opin. Drug Saf. 2009; 8(6): 615-626.
  20. Chu F. Current therapeutic research. 2009; 70(6): 405-420.
  21. Haab F., Cardozo L., Chapple C. et al. for th Solifenacin Study Group: Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Europian Urology. 2005; 47(3): 376-384.
  22. Cardozo L., Amarenco G., Pushkar D. et al. on behalf of the SUNRISE Study Group. Severity of overactive bladder symptoms and response to dose escalation in randomized, double-blind trial of solifenacin (SUNRISE). 2013; BJU International, poblished online.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies